Trial Profile
Phase II Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 12 Feb 2024 Planned End Date changed from 1 Jan 2024 to 1 Apr 2024.
- 12 Dec 2023 Planned End Date changed from 1 Oct 2023 to 1 Jan 2024.
- 15 Feb 2020 Results (n=60) assessing on-therapy changes in circulating immune cells and cytokines and their association with outcomes, presented at the 2020 Genitourinary Cancers Symposium.